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The survey had a 62% completion rate. Supplemental Table I (available at http://www. jaad.org) summarized the characteristics of the 31 responding clinics. Each half-day outpatient dermatology clinic had a median of 48 (interquartile range [IQR] 30-60) patients scheduled. The median no-show rate for these scheduled appointments was 30% (IQR 24.25%-35%). The median wait time until the third next-available appointment for a new and follow-up patient was 45 (IQR 30-90) days and 30 (IQR 16.5-55) days, respectively (Table I) . Each half-day dermatology clinic had a median of 3 (IQR 1.75-4) providers per nurse, and 2 (IQR 2-4) providers per medical assistant (Table II) . Most clinics offered select dermatology subspecialty services (eg, dermatopathology and pediatric dermatology) and treatments (eg, phototherapy and patch testing) (Supplemental Fig 1; available at http://www.jaad.org).
The 30% no-show rate is similar to nonattendance rates among patients with state-supported insurance (26%). 2 High no-show rates in the safety-net outpatient dermatology clinics, which can be due to transportation constraints and inability to take leave from work, can result in increased wait times for appointment availability. Our survey revealed a mean wait time of 45 days for a new patient visit, compared with 29.1 days according to the 2014 American Academy of Dermatology Practice Survey, which compiled data from practicing dermatologists across the United States. 3 Extended wait times can be compounded by understaffing issues. Although optimal staffing for outpatient dermatology clinics is not known, staffing ratios reported by safety-net dermatology clinics are less than ideal, as providers outnumber support staff. Hiring additional nursing staff can help improve clinic productivity and reduce wait times. For example, the increase from 1 nurse per provider to 2 nurses led to a 30% increase in completed visits at 1 university hospital dermatology clinic. 4 In the outpatient dermatology clinic at Parkland Health and Hospital System in Dallas, Texas, the hiring of an additional nurse resulted in a 31% decrease in wait times. 5 Our survey of safety-net dermatology clinics revealed that they have long wait times for appointment availability, high no-show rates, and are understaffed in regards to medical assistants and nurses. Limitations included small sample size, urban location of all surveyed clinics, and lack of standardized definition of safety-net hospital. The need to characterize gaps in dermatologic care for underserved populations is crucial to allow for improved allocation of the limited financial resources at safety-net hospitals. To the Editor: Recent reports document successful treatment of alopecia areata (AA) with tofacitinib.
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However, long-term data using tofacitinib monotherapy is still sparse, and we are unaware of the quality of treatment in persons of Asian decent. We report the results of extended tofacitinib monotherapy in adult Korean patients with moderate-to-severe AA. After obtaining approval by the institutional review board, we retrospectively reviewed a prospective database having 32 patients with [30% hair loss who had undergone $4 months of treatment (Table I) . Most (29, 90.6%) patients were refractory to previous treatments, which included oral steroid and cyclosporine. Alopecia severity had been recorded using the Severity of Alopecia Tool (SALT). SALT 50 and SALT 90 were defined by 50% and 90% regrowth, respectively.
Twenty-four patients (75.0%) exhibited [5% hair regrowth: 6 with 5%-50% regrowth (median duration and median total dose of tofacitinib; 7 months and 1960 mg, respectively); 9 with 50%-90% regrowth (9 months and 1820 mg, respectively); and 9 with [90% regrowth (10 months and 2240 mg, respectively). Eight patients showed no response (median duration and median total dose of tofacitinib; 6 months and 2240 mg, respectively). Eighteen patients (56.3%) achieved SALT 50 at a median of 3 (range 2-10) months, and 9 patients (28.1%) acquired SALT 90 at a median of 6 (range 4-11) months. All of them achieved SALT 50 or SALT 90 on a 5-mg twice daily regimen. In 6 patients, the dose was increased (up to 20 mg/day), which accelerated hair regrowth but did not result in SALT 50 during the follow-up period. Two of 18 SALT 50 achievers (11.1%) deteriorated after the initial response but Supplemental Fig 1. Dermatology clinic services and subspecialists at safety-net hospitals.
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